Pfizer Antes Up $110 Million To Buy In To Cancer Cell Therapy Race - Presented by: The Aol. On Network

Fresh from its failed (or at least paused) attempt to acquire rival AstraZeneca, Pfizer has made a big bet on one of the hottest new technologies in cancer: genetically engineered white blood cells that hunt down tumors and destroy them. Pfizer announced this morning that it will pay Cellectis, a French biotechnology company, an $80 million upfront payment for the company’s T-cell technology, in addition to purchasing about $30 million in stock.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 18.02 0.04 ▲ 0.22%
AAPL $ 113.115 1.11 ▲ 0.99%
RAD $ 7.45 0.19 ▲ 2.62%
GRPN $ 8.37 0.48 ▲ 6.08%
GILD $ 93.3698 2.08 ▲ 2.28%
GPRO $ 68.945 2.54 ▲ 3.82%
PBR $ 7.54 0.06 ▼ 0.79%
ABX $ 10.73 0.42 ▲ 4.07%

As of 12/26/2014, 12:28 PM
More Most Active